Genzyme Corp

Genzyme — Merger or Acquisition (February 2011)

13 slides from Genzyme's merger presentation, Feb 16, 2011

  1. Slide 1: Sanofi-aventis Town hall meeting

    Sanofi-aventis Town hall meeting February 16 th , 2011

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Important Information about this Transaction This communication is neither an offer to purchase nor a solicitation of any offer to sell any securities. In connection with the proposed transaction, sanofi-aventis will file an amended tender offer statement and a registratio

  3. Slide 3: “ sanofi ave

    “ sanofi ave

  4. Slide 4: Sanofi-aventis - A world leader

    30,384 Sanofi-aventis - A world leader € 30,384 m 2010 NET SALES-GROSS OF 3,7% COMPARED WITH 2009 ON A REPORTED BASIS 100,000 More than 100,000 EMPLOYEES WORLDWIDE ONE OF THE LARGEST PHARMACEUTICAL GROUPS IN THE WORLD

  5. Slide 5: Core growth platforms

    - A global sustainable healthcare partner focused on patients’ needs - Recognised for our ability to transform scientific innovation into hope and solutions for patients Achieving our ambition through core growth platforms Growth platforms Diabetes Vaccines Emerging Markets Consumer Health Care Inno

  6. Slide 6: Our response to health issues

    Diabetes Oncology Cardiovascular Atrial Fibrillation Vaccines Consumer Heath Care Our response to health issues

  7. Slide 7: Our culture

    Our culture CONFIDENCE INNOVATION RESPECT SOLIDARITY INTEGRITY

  8. Slide 8: Town hall meeting

    Town hall meeting February 16 th , 2011

  9. Slide 9: General principles for working together

    General principles for working together Acknowledge and recognize your unique know-how and build on your DNA Genzyme brand Greater Boston Area Listen to you, understand your business and create a collaborative spirit to take this forward together Focus on the day-to-day business and continue to addr

  10. Slide 10: Organization for integration

    Organization for integration • Chris Viehbacher (co-chair) • Belén Garijo (Integration Leader) • Jérôme Contamine (Finance) • Karen Linehan (Legal) • Roberto Pucci (HR) • Laure Thibaud (Comm.) • Philippe Luscan (IA) adhoc • Elias Zerhouni (R&D) adhoc • Sanofi-aventis and Genzyme representation to be

  11. Slide 11: Proposed high-level organization for integration

    Manufacturing Proposed high-level organization for integration HR integration support & talent management Internal/external communication Metrics Process management / guidelines Finance HR Purchasing Legal IT Real Estate Quality work streams (business assessment, strategy, integration model) Communi

  12. Slide 12: High-level calendar

    Understanding and planning Business continuity and integration country level kick off High-level calendar Q1 Q2 Q3 Q4 Legal process (tender offer, CVR registration) Feb th Merger agreement Transaction closing / Day 1 Feb 16 th Global Kick-off pre-integration Legal process Pre-integration work Integr

  13. Slide 13: Questions & answers

    Questions & answers

Genzyme — Merger or Acquisition (February 2011) on 6ix